A phase 1/2 clinical trial assessing Excindogen for advanced stage pancreatic cancer
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Excindogen (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vitalgenics
- 17 Sep 2021 New trial record
- 10 Sep 2021 According to Vitalgenics Inc media release, the company is seeking capital to enter this phase 1/2 clinical trial and FDA submissions for advanced stage pancreatic cancer